SLDB

Solid Biosciences is a clinical-stage gene therapy company with effectively zero commercial revenue (FY2025 revenue is not reported; the last meaningful figure was $8.09M in FY2022, down 40.6% YoY) and a $174.3M FY2025 net loss that the 10-K explicitly flags will grow as the company enrolls the INSPIRE DUCHENNE, IMPACT DUCHENNE, FALCON and ARTEMIS trials. The accumulated deficit of $957.8M and operating cash burn of -$156M against just $59.9M of cash (down 25.3% YoY) is the central problem: at current burn the company has well under a year of runway, and management states in Risk Factors that 'expenses will increase substantially' — meaning a dilutive raise is not a tail risk, it is a near-certain event. Shares outstanding already grew 27.0% in FY2025, foreshadowing the path.

The lead asset SGT-003 for Duchenne muscular dystrophy has real scientific momentum — FDA Fast Track, Orphan Drug and Rare Pediatric Disease designations, a UK Innovation Passport, and positive March 2026 interim Phase 1/2 data with 41 participants dosed and a 'generally well tolerated' safety profile on a low-burden steroid-only immunomodulation regimen. But the MD&A also discloses a Grade 3 immune-mediated myositis serious adverse event, and the company is still amending protocols and initiating additional GMP manufacturing batches — i.e., the program is mid-development, not near approval. Management notes 'it could be several years before we have a commercialized product, and we may never have a commercialized product,' and that SGT-001 was already abandoned. The pipeline (SGT-212, SGT-501, SGT-601) is even earlier.